- Home
- PGZ vs RFL Comparison
PGZ vs RFL Comparison
Compare PGZ & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PGZ | RFL |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.4M | 63.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PGZ | RFL |
|---|---|---|
| Price | $9.96 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.8K | ★ 61.2K |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 12.26% | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $9.24 | $1.12 |
| 52 Week High | $10.68 | $3.19 |
Technical Indicators
Market Signals| Indicator | PGZ | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 51.17 | 43.82 |
| Support Level | $9.32 | $1.15 |
| Resistance Level | $10.58 | $1.59 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 80.92 | 13.04 |
Price Performance
Historical ComparisonAbout PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Germany, Singapore, South Korea, British Virgin Islands and more.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.